Market Dynamics: The global Sjögren’s syndrome market is poised for a stable revenue compound annual growth rate (CAGR) in the forecast period. Key drivers fueling market revenue growth include the increasing prevalence of Sjögren’s syndrome and a robust pipeline of treatments for the condition.
Sjögren’s Syndrome Symptoms: Sjögren’s syndrome is characterized by two prominent symptoms: dry eyes and a dry mouth. This autoimmune disorder often worsens in middle adulthood and primarily targets the salivary and lacrimal glands, leading to impaired tear and saliva production. Dry eyes manifest as itching, burning, sand-like sensations, blurry vision, and light sensitivity. A dry mouth can hinder speech, taste, and swallowing, often feeling chalky or cotton-filled. People with Sjögren’s syndrome are more susceptible to tooth decay and oral infections due to reduced saliva’s protective function. The condition can also impact other tissues and organs, causing various symptoms like muscle and joint inflammation, skin issues, persistent cough, hoarseness, kidney and liver problems, numbness, dryness in women, and severe fatigue. In rare cases, individuals with Sjögren’s syndrome may develop Lymphoma.
Causes of Sjögren’s Syndrome: The exact cause of Sjögren’s syndrome is not determined, but it is believed to result from a combination of genetic and environmental factors. Genetic variations in several genes may influence the likelihood of developing the syndrome, while viral or bacterial infections that activate the immune system can elevate the risk in predisposed individuals.
Get a sample copy of the Sjogrens Syndrome Treatment Market report: https://www.reportsanddata.com/download-free-sample/5720
Factors Driving Market Growth: Drivers: The increasing incidence of Sjogren’s syndrome and other autoimmune diseases is a major driver of market revenue growth. Additionally, the market for Sjogren’s drugs and medical products is expected to expand due to growing income levels, increased awareness of preventive healthcare, a rising elderly population, demand for advanced Sjogren’s syndrome treatment, a larger patient population with related diseases like lupus and rheumatoid arthritis, intensified research and development activities, and government initiatives.
Restraints: High care costs and the severe consequences of Sjogren’s disease, such as dehydration, significant weight loss, and inflammation, are expected to impede market revenue growth. Lack of awareness about the condition, preventive measures, and drug side effects are other factors that may restrain revenue growth. Additionally, strict government regulations, high costs, and scleroderma diagnostic tests are significant factors hampering market revenue growth.
Opportunities: Ongoing research and development in the rare disease diagnosis and medical specialization field are expected to create new opportunities for market players during the forecast period.
Geographic Market Scenario: Largest Market Share: The North American market is anticipated to exhibit the highest revenue CAGR in the Sjögren’s syndrome market during the forecast period. This is attributed to the presence of significant key players, high disposable income, and a well-established healthcare system in North America.
Fastest Growing Region: The Asia Pacific market is expected to experience steady revenue growth during the forecast period, driven by increased research and development efforts, rising healthcare expenditure, and government support.
What Our Report Provides and Why Our Offering Is Better: This report provides historical data, forecasts, and revenue growth at global, regional, and country levels. It offers analysis, industry trends, and consumption patterns for each region, major country, and segment from 2019 to 2030. The global market report encompasses industry trends, drivers, restraints, opportunities, threats, market strategies, segment revenue, and revenue share contributions by each regional and country market. Additionally, it includes industry analysis, competitive landscape, company financials, and impact analysis.
Organic and Inorganic Strategies Adopted: Since June 2021, The Center for Ophthalmic and Vision Research, LLC has been conducting a Phase IV clinical trial study in partnership with Sun Pharmaceutical Industries Limited to demonstrate how CEQUA (cyclosporine 0.09% ophthalmic solution) reduces the symptoms of dry eye disease in patients with a diagnosis of Sjogren’s Syndrome.
Key Market Trends and Innovation: Since January 2022, Dompe Farmaceutici S.p.A. has been conducting a Phase III clinical trial research to evaluate the effectiveness and safety of cenegermin (rhNGF) ophthalmic solution at a concentration of 20 mcg/mL given three times per day for four weeks in patients with severe Sjogren’s Dry Eye Disease (DED) who are receiving ongoing treatment with topical cyclosporine A.
Since January 2022, a Phase IV clinical trial investigation on the effectiveness and safety of iguratimod in patients with Primary Sjögren’s syndrome has been going on at the Second Affiliated Hospital, School of Medicine, Zhejiang University.
Since September 2021, Fish Oil (Omega 3) in patients with Sjögren’s Syndrome is the subject of a Phase III clinical trial carried out by Hawker Medical University.
Since May 2021, Sylentis, S.A. has been running a Phase III clinical research study to look at the effectiveness and security of tivanisiran sodium eye drops in people who have Sjögren’s Syndrome-related dry eye disease (DED).
Since March 2021, a Phase IV clinical trial investigation has been underway at China Medical University Hospital to determine the beta-3 agonist and anti-muscarinic agents’ therapeutic impact on patients with Sjogren’s syndrome who have overactive bladders.
Since June 2019, a Phase III clinical trial research of Polyvalent Intravenous Immunoglobulins for the treatment of Primary Sjögren’s Syndrome associated with painful sensory neuropathies has been going on at University Hospital, Strasbourg, France.
Major Companies in the Market Include:
- GSK plc
- Pfizer Inc.
- Novartis AG
- Johnson and Johnson Services, Inc.
- Sun Pharmaceutical Industries Ltd.
- Start-Ups & Innovator Key Players
- Catena Biosciences
Scope of The Report: Product Type Outlook (Revenue, USD Billion; 2019-2030):
- Tablets
- Capsules
- Injectables
- Others
Route of Administration Outlook (Revenue, USD Billion; 2019-2030):
- Oral
- Parenteral
- Others
Disease Type Outlook (Revenue, USD Billion; 2019-2030):
- Primary
- Secondary
Distribution Channel Outlook (Revenue, USD Billion; 2019-2030):
- Online
- Offline
End-user Outlook (Revenue, USD Billion; 2019-2030):
- Hospital Pharmacy
- Retail Pharmacy
- Specialty Clinics
Regional Outlook (Revenue, USD Million; 2019-2030):
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Benelux
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia Pacific
- Latin America
- Brazil
- Rest of Latin America
- Middle East & Africa
- Saudi Arabia
- U.A.E.
- South Africa
- Rest of Middle East & Africa
Explore Trending Reports:
Face Recognition Systems Market-https://www.globenewswire.com/news-release/2019/05/23/1841952/0/en/Face-Recognition-Systems-Market-To-Reach-USD-11-30-Billion-By-2026-Reports-And-Data.html
Applicant Tracking System Market-https://www.globenewswire.com/news-release/2019/07/22/1885923/0/en/Applicant-Tracking-System-ATS-Market-To-Reach-USD-2-34-Billion-By-2026-Reports-And-Data.html
Infrastructure as a Service (IaaS) Market-https://www.globenewswire.com/news-release/2019/11/12/1945014/0/en/Infrastructure-as-a-Service-IaaS-Market-To-Reach-USD-238-87-Billion-By-2026-Reports-And-Data.html
Power Over Ethernet (POE) Lighting Market-https://www.globenewswire.com/news-release/2019/04/02/1795631/0/en/Power-Over-Ethernet-POE-Lighting-Market-To-Reach-USD-1-27-Billion-By-2026.html
Request a customization of the report: https://www.reportsanddata.com/request-customization-form/5720
Thank you for reading our report. To know more about the customization or any query about the report contents, please connect with us and our team will ensure the report is tailored to meet your requirements.
About Reports and Data
Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyse consumer behaviour shifts across demographics, across industries, and help clients to make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Products, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provides our clients with the ability to secure an edge over their respective competitors.
Contact Us:
John W
(Head of Business Development)
Reports and Data | Web: www.reportsanddata.com
Direct Line: +1-212-710-1370
E-mail: sales@reportsanddata.com
Blogs | Press Release | Industry News | Our competencies
Browse More Upcoming Reports @ https://www.reportsanddata.com/upcoming-reports
Browse More Latest Reports @ https://www.reportsanddata.com/report
Browse Latest Blogs: https://www.reportsanddata.com/blogs
Browse Latest Press Release: https://www.reportsanddata.com/press-release